Today "Big Five Fatigue" is spreading among sponsors. Symptoms vary but can quickly become severe:

• Lethargy

  First-patient-in is behind schedule, and no one seems to have an answer why. It feels like your trial is just one of many your Big Five CRO is dealing with, and your project team seems more interested in checking a box then digging into the issues. Precision people are assigned to just two to three trials at a time.

• Budget Creep

  With a Big Five CRO, timelines and budgets can shift, often without clear rationale. Scope changes or additions? Those can drive costs up quickly. Even at times when those costs could have been avoided. Precision keeps costs under control with amendment management.

   

• Start-up Inertia

  Have an early-phase oncology trial that needs rapid patient recruitment? Your Big Five CRO may not specialize in pre-vetting oncology organizations to meet the need for speed. The Precision Site Network includes 100+ pre-vetted oncology sites and speed to FIH that other CROs find difficult to match.

• High Turnover

  If you’re working with a Big Five CRO, chances are that every few months a new project manager introduces themselves.
  They must “get up to speed.” Again. At Precision, we have just 8% employee turnover versus 20% for the industry.

• Lack of focus

  Your trial isn't getting the focused attention it needs. Teams rotate frequently, and you're often working with generalists instead of dedicated specialists. Precision teams specialize in complex, high-precision trials in areas like oncology, gene therapy and rare diseases.

• Lost in the Shuffle

  Have a question? Prepare to wait for the person who can answer. At Precision, you get direct access to decision-makers and a proactive team that moves at your speed.

• Temporary Amnesia

  The Big Five chase big budget trials and when a new, bigger trial comes in, they may forget their promises when it comes to smaller, more specialized trials. At Precison 56% of our trials are early phase and 70% are oncology focused.

• Regulatory Confusion

  Running blind? Rare disease and biomarker treatments can often have no regulatory precedent. Precision’s experience with the FDA submissions for innovative treatments can shed light.

• Lack of Flexibility

  Need to adjust your protocol or inclusion parameters? Change a process? Too bad. You’re stuck in their rigid system. Precision is a right-sized CRO with a much more responsive approach. When change happens mid-trial, we can handle it.

• Financial Headaches

  Funding is tight, and the biotech capital landscape is shifting. You need a partner who understands financing and can help you secure capital now. Precision’s Investor Relations team has helped raise $30 billion in five years for biotech companies.